Curis Inc (CRIS) 1.69 $CRIS
Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 08, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that updated data from the Phase 1 trial of CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 21 Congress of the European Hematology Association to be held from June 9-12 in Copenhagen, Denmark.
CRIS: 1.69 (-0.10)
Curis to Present at the Jefferies Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:15AM CDT
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President & Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 8, 2016, at 2:00 p.m. Eastern Time in New York City.
CRIS: 1.69 (-0.10)
Curis Announces Presentations Related to CUDC-907 and Erivedge(R) at 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that a Phase 2 trials-in-progress poster for CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from June 3-7 in Chicago, IL.
CRIS: 1.69 (-0.10)
Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for CA-170. CA-170 is a first-in-class orally available small molecule that has been designed to target and inhibit the immune checkpoints, Programmed Death Ligand-1 (PD-L1) and V-domain Immunoglobulin Suppressor of T-cell Activation (VISTA).
CRIS: 1.69 (-0.10)
Curis to Release First Quarter 2016 Financial Results and Hold Conference Call on May 9, 2016
GlobeNewswire - Mon May 02, 6:34AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter 2016 financial results on Monday, May 9, 2016, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT.
CRIS: 1.69 (-0.10)
Curis Announces Presentation of Preclinical Data from CUDC-907, CA-170 and PD-L1/TIM-3 Antagonist and CA-4948 Programs at AACR Annual Meeting
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that Curis scientists and its collaborator, Aurigene will present data from multiple programs at the Annual Meeting of American Association of Cancer Research (AACR) to be held from April 16 - 20, 2016 in New Orleans, LA.
CRIS: 1.69 (-0.10)
Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology
GlobeNewswire - Mon Apr 04, 6:00AM CDT
-- Latest analysis of data presented at the American Society of Hematology's annual meeting in December, 2015 --
CRIS: 1.69 (-0.10)
Curis Announces Expansion of Executive Team
GlobeNewswire - Wed Mar 30, 6:00AM CDT
-- James Dentzer joins Curis as Chief Financial and Chief Administrative Officer --
CRIS: 1.69 (-0.10)
Curis to Present at the 28th Annual Roth Conference
GlobeNewswire - Tue Mar 08, 6:00AM CST
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Mani Mohindru, Ph.D., Senior Vice President, Corporate Strategy & Investor Relations, will present at the 28 Annual Roth Conference on March 15, 2016, at 10:30 a.m. Pacific Time in Dana Point, CA.
CRIS: 1.69 (-0.10)
Global Curis, Inc. Market Latest Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 7:34AM CST
'CURIS, INC. - Product Pipeline Review - 2015', provides an overview of the CURIS, INC.'s pharmaceutical research and development focus.
CRIS: 1.69 (-0.10)
Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.69 (-0.10), IMMU: 3.05 (-0.08), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), EPZM: 11.86 (-0.40), BIND: 0.40 (-0.01), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), CTIC: 0.43 (-0.01), IDRA: 1.50 (-0.07), CYCC: 5.95 (-0.14), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), ABBV: 61.00 (+0.25), CBMG: 15.16 (+0.22), CELGZ: 1.46 (-0.04)
Curis to Present at the BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 3:05PM CST
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President and Chief Executive Officer, will present at the BIO CEO & Investor Conference, February 8, 2016, at 5:30 p.m. Eastern Time in New York City.
CRIS: 1.69 (-0.10)
Follicular Lymphoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/38wlhh/follicular) has announced the addition of the "Follicular Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Follicular Lymphoma , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AbbVie Inc. - Affimed Therapeutics AG - Bayer AG - BeiGene(Beijing) Co.,Ltd - Bio-Path Holdings, Inc. - Biocon Limited - Biogenomics Limited - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Cellular Biomedicine Group, Inc. - Coherus BioSciences, Inc. - CTI BioPharma Corp. - Curis, Inc. - Dynavax Technologies Corporation - (30 Others) Key Topics Covered: - Introduction - Follicular Lymphoma Overview - Therapeutics Development - Pipeline Products for Follicular Lymphoma - Overview - Pipeline Products for Follicular Lymphoma - Comparative Analysis - Follicular Lymphoma - Therapeutics under Development by Companies - Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes - Follicular Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Follicular Lymphoma - Products under Development by Companies - Follicular Lymphoma - Products under Investigation by Universities/Institutes - Follicular Lymphoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/38wlhh/follicular
DVAX: 14.59 (-0.46), CRIS: 1.69 (-0.10), BPTH: 2.43 (-0.01), ABBV: 61.00 (+0.25), CTIC: 0.43 (-0.01), BMY: 72.65 (-0.08), CBMG: 15.16 (+0.22), CHRS: 16.01 (-0.94), CELGZ: 1.46 (-0.04)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Review 2015
M2 - Thu Jan 14, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/mkmlnh/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Multiple Myeloma Overview - Therapeutics Development - Pipeline Products for Relapsed Multiple Myeloma - Overview - Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis - Relapsed Multiple Myeloma - Therapeutics under Development by Companies - Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes - Relapsed Multiple Myeloma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Multiple Myeloma - Products under Development by Companies - Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes - Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - Cleave Biosciences - Curis, Inc. - Daiichi Sankyo Company, Limited - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - IGF Oncology, LLC. - Immunomedics, Inc. - Jasco Pharmaceuticals, LLC. - Johnson & Johnson - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Noxxon Pharma AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Patrys Limited - Pfizer Inc. - Pharma Mar, S.A. - Sanofi For more information visit http://www.researchandmarkets.com/research/mk...d_multiple
CLRB: 3.29 (-0.15), CRIS: 1.69 (-0.10), IMMU: 3.05 (-0.08), ONCY: 0.33 (-0.02), PFE: 35.29 (-0.02), AMGN: 154.78 (-2.00), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), JNJ: 117.01 (+0.01), MRK: 56.81 (-0.37), CALA: 4.80 (-0.25), ABBV: 61.00 (+0.25), NVS: 78.94 (-1.57), EXEL: 7.38 (+0.01), ARRY: 3.51 (-0.01), CELGZ: 1.46 (-0.04)
Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors
GlobeNewswire - Fri Jan 08, 7:10AM CST
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the election of Marc Rubin, M.D. as Chairman of the Board of Directors. Dr. Rubin, who has been serving as lead independent Director, succeeds James C. Czirr, who helped found the Company in 2000 and has served as Executive Chairman for the past seven years. Mr. Czirr will continue to serve as a Director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and Board experience in the development and commercialization of pharmaceuticals.
CRIS: 1.69 (-0.10), TTNP: 6.43 (+0.34), GALT: 1.42 (-0.05)
Biotechnology Equity Picks - Arena Pharma, uniQure, Cytokinetics, and Curis
ACCESSWIRE - Wed Jan 06, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2016 / Park Lane Advisor has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), uniQure N.V. (NASDAQ: QURE), Cytokinetics Inc. (NASDAQ: CYTK), and Curis Inc. (NASDAQ: CRIS). Free research report on Arena Pharma can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 05, 2016, the NASDAQ Composite ended at 4,891.43, down 0.24%, the Dow Jones Industrial Average edged 0.06% higher, to finish the day at 17,158.66, and the S&P 500 closed at 2,016.71, up 0.20%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CYTK: 8.21 (-0.09), CRIS: 1.69 (-0.10), QURE: 11.81 (-0.33), ARNA: 1.99 (-0.07)
Can Walgreens Boots (WBA) Retain its Earnings Streak in Q1?
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 8:00AM CST
So far, the legacy Walgreens' partnership with Alliance Boots has yielded positive results, with combined synergies totaling $799 million in fiscal 2015 for Walgreens Boots (WBA)
FATE: 1.65 (-0.05), CRIS: 1.69 (-0.10), WBA: 82.47 (+3.46), IDXX: 88.88 (-1.37)
Biotechnology Equities Ahead of Market -- Regulus Therapeutics, Ocata Therapeutics, Vanda Pharma, and Curis
ACCESSWIRE - Wed Dec 30, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / December 30, 2015 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Ocata Therapeutics Inc. (NASDAQ: OCAT), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Curis Inc. (NASDAQ: CRIS). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Tuesday, December 29, 2015, the NASDAQ Composite ended at 5,107.94, up 1.33%, the Dow Jones Industrial Average advanced 1.10%, to finish the day at 17,720.98, and the S&P 500 closed at 2,078.36, up 1.06%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CRIS: 1.69 (-0.10), OCAT: 8.47 (+0.01), VNDA: 10.81 (-0.17), RGLS: 5.27 (-0.07)
Will Curis (CRIS) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Fri Dec 18, 9:19AM CST
As of late, it has definitely been a great time to be an investor Curis, Inc. (CRIS)
CRIS: 1.69 (-0.10)
Technical Briefing on Biotechnology Equities -- Keryx Biopharma, Cytokinetics, Curis, and BioTime
ACCESSWIRE - Thu Dec 17, 7:03AM CST
NEW YORK, NY / ACCESSWIRE / December 17, 2015 / Park Lane Advisor has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Cytokinetics Inc. (NASDAQ: CYTK), Curis Inc. (NASDAQ: CRIS), and BioTime Inc. (AMEX: BTX). Free research report on Keryx Biopharma can be accessed at http://www.parklaneadvisor.com/ On Wednesday, December 16, 2015, the NASDAQ Composite ended at 5,071.13, up 1.52%, the Dow Jones Industrial Average advanced 1.28%, to finish the day at 17,749.09, and the S&P 500 closed at 2,073.07, up 1.45%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
CYTK: 8.21 (-0.09), CRIS: 1.69 (-0.10), BTX: 2.74 (-0.03), KERX: 5.93 (-0.12)
Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 08, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that updated data from the Phase 1 trial of CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 21 Congress of the European Hematology Association to be held from June 9-12 in Copenhagen, Denmark.
CRIS: 1.69 (-0.10)
Curis to Present at the Jefferies Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:15AM CDT
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President & Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 8, 2016, at 2:00 p.m. Eastern Time in New York City.
CRIS: 1.69 (-0.10)
Curis Announces Presentations Related to CUDC-907 and Erivedge(R) at 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that a Phase 2 trials-in-progress poster for CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from June 3-7 in Chicago, IL.
CRIS: 1.69 (-0.10)
Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for CA-170. CA-170 is a first-in-class orally available small molecule that has been designed to target and inhibit the immune checkpoints, Programmed Death Ligand-1 (PD-L1) and V-domain Immunoglobulin Suppressor of T-cell Activation (VISTA).
CRIS: 1.69 (-0.10)
Curis to Release First Quarter 2016 Financial Results and Hold Conference Call on May 9, 2016
GlobeNewswire - Mon May 02, 6:34AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter 2016 financial results on Monday, May 9, 2016, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT.
CRIS: 1.69 (-0.10)
Curis Announces Presentation of Preclinical Data from CUDC-907, CA-170 and PD-L1/TIM-3 Antagonist and CA-4948 Programs at AACR Annual Meeting
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that Curis scientists and its collaborator, Aurigene will present data from multiple programs at the Annual Meeting of American Association of Cancer Research (AACR) to be held from April 16 - 20, 2016 in New Orleans, LA.
CRIS: 1.69 (-0.10)
Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology
GlobeNewswire - Mon Apr 04, 6:00AM CDT
-- Latest analysis of data presented at the American Society of Hematology's annual meeting in December, 2015 --
CRIS: 1.69 (-0.10)
Curis Announces Expansion of Executive Team
GlobeNewswire - Wed Mar 30, 6:00AM CDT
-- James Dentzer joins Curis as Chief Financial and Chief Administrative Officer --
CRIS: 1.69 (-0.10)
Curis to Present at the 28th Annual Roth Conference
GlobeNewswire - Tue Mar 08, 6:00AM CST
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Mani Mohindru, Ph.D., Senior Vice President, Corporate Strategy & Investor Relations, will present at the 28 Annual Roth Conference on March 15, 2016, at 10:30 a.m. Pacific Time in Dana Point, CA.
CRIS: 1.69 (-0.10)
Global Curis, Inc. Market Latest Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 7:34AM CST
'CURIS, INC. - Product Pipeline Review - 2015', provides an overview of the CURIS, INC.'s pharmaceutical research and development focus.
CRIS: 1.69 (-0.10)
Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.69 (-0.10), IMMU: 3.05 (-0.08), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), EPZM: 11.86 (-0.40), BIND: 0.40 (-0.01), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), CTIC: 0.43 (-0.01), IDRA: 1.50 (-0.07), CYCC: 5.95 (-0.14), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), ABBV: 61.00 (+0.25), CBMG: 15.16 (+0.22), CELGZ: 1.46 (-0.04)
Curis to Present at the BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 3:05PM CST
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President and Chief Executive Officer, will present at the BIO CEO & Investor Conference, February 8, 2016, at 5:30 p.m. Eastern Time in New York City.
CRIS: 1.69 (-0.10)
Follicular Lymphoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/38wlhh/follicular) has announced the addition of the "Follicular Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Follicular Lymphoma , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AbbVie Inc. - Affimed Therapeutics AG - Bayer AG - BeiGene(Beijing) Co.,Ltd - Bio-Path Holdings, Inc. - Biocon Limited - Biogenomics Limited - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Cellular Biomedicine Group, Inc. - Coherus BioSciences, Inc. - CTI BioPharma Corp. - Curis, Inc. - Dynavax Technologies Corporation - (30 Others) Key Topics Covered: - Introduction - Follicular Lymphoma Overview - Therapeutics Development - Pipeline Products for Follicular Lymphoma - Overview - Pipeline Products for Follicular Lymphoma - Comparative Analysis - Follicular Lymphoma - Therapeutics under Development by Companies - Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes - Follicular Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Follicular Lymphoma - Products under Development by Companies - Follicular Lymphoma - Products under Investigation by Universities/Institutes - Follicular Lymphoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/38wlhh/follicular
DVAX: 14.59 (-0.46), CRIS: 1.69 (-0.10), BPTH: 2.43 (-0.01), ABBV: 61.00 (+0.25), CTIC: 0.43 (-0.01), BMY: 72.65 (-0.08), CBMG: 15.16 (+0.22), CHRS: 16.01 (-0.94), CELGZ: 1.46 (-0.04)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Review 2015
M2 - Thu Jan 14, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/mkmlnh/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Multiple Myeloma Overview - Therapeutics Development - Pipeline Products for Relapsed Multiple Myeloma - Overview - Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis - Relapsed Multiple Myeloma - Therapeutics under Development by Companies - Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes - Relapsed Multiple Myeloma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Multiple Myeloma - Products under Development by Companies - Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes - Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - Cleave Biosciences - Curis, Inc. - Daiichi Sankyo Company, Limited - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - IGF Oncology, LLC. - Immunomedics, Inc. - Jasco Pharmaceuticals, LLC. - Johnson & Johnson - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Noxxon Pharma AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Patrys Limited - Pfizer Inc. - Pharma Mar, S.A. - Sanofi For more information visit http://www.researchandmarkets.com/research/mk...d_multiple
CLRB: 3.29 (-0.15), CRIS: 1.69 (-0.10), IMMU: 3.05 (-0.08), ONCY: 0.33 (-0.02), PFE: 35.29 (-0.02), AMGN: 154.78 (-2.00), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), JNJ: 117.01 (+0.01), MRK: 56.81 (-0.37), CALA: 4.80 (-0.25), ABBV: 61.00 (+0.25), NVS: 78.94 (-1.57), EXEL: 7.38 (+0.01), ARRY: 3.51 (-0.01), CELGZ: 1.46 (-0.04)
Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors
GlobeNewswire - Fri Jan 08, 7:10AM CST
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the election of Marc Rubin, M.D. as Chairman of the Board of Directors. Dr. Rubin, who has been serving as lead independent Director, succeeds James C. Czirr, who helped found the Company in 2000 and has served as Executive Chairman for the past seven years. Mr. Czirr will continue to serve as a Director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and Board experience in the development and commercialization of pharmaceuticals.
CRIS: 1.69 (-0.10), TTNP: 6.43 (+0.34), GALT: 1.42 (-0.05)
Biotechnology Equity Picks - Arena Pharma, uniQure, Cytokinetics, and Curis
ACCESSWIRE - Wed Jan 06, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2016 / Park Lane Advisor has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), uniQure N.V. (NASDAQ: QURE), Cytokinetics Inc. (NASDAQ: CYTK), and Curis Inc. (NASDAQ: CRIS). Free research report on Arena Pharma can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 05, 2016, the NASDAQ Composite ended at 4,891.43, down 0.24%, the Dow Jones Industrial Average edged 0.06% higher, to finish the day at 17,158.66, and the S&P 500 closed at 2,016.71, up 0.20%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CYTK: 8.21 (-0.09), CRIS: 1.69 (-0.10), QURE: 11.81 (-0.33), ARNA: 1.99 (-0.07)
Can Walgreens Boots (WBA) Retain its Earnings Streak in Q1?
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 8:00AM CST
So far, the legacy Walgreens' partnership with Alliance Boots has yielded positive results, with combined synergies totaling $799 million in fiscal 2015 for Walgreens Boots (WBA)
FATE: 1.65 (-0.05), CRIS: 1.69 (-0.10), WBA: 82.47 (+3.46), IDXX: 88.88 (-1.37)
Biotechnology Equities Ahead of Market -- Regulus Therapeutics, Ocata Therapeutics, Vanda Pharma, and Curis
ACCESSWIRE - Wed Dec 30, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / December 30, 2015 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Ocata Therapeutics Inc. (NASDAQ: OCAT), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Curis Inc. (NASDAQ: CRIS). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Tuesday, December 29, 2015, the NASDAQ Composite ended at 5,107.94, up 1.33%, the Dow Jones Industrial Average advanced 1.10%, to finish the day at 17,720.98, and the S&P 500 closed at 2,078.36, up 1.06%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CRIS: 1.69 (-0.10), OCAT: 8.47 (+0.01), VNDA: 10.81 (-0.17), RGLS: 5.27 (-0.07)
Will Curis (CRIS) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Fri Dec 18, 9:19AM CST
As of late, it has definitely been a great time to be an investor Curis, Inc. (CRIS)
CRIS: 1.69 (-0.10)
Technical Briefing on Biotechnology Equities -- Keryx Biopharma, Cytokinetics, Curis, and BioTime
ACCESSWIRE - Thu Dec 17, 7:03AM CST
NEW YORK, NY / ACCESSWIRE / December 17, 2015 / Park Lane Advisor has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Cytokinetics Inc. (NASDAQ: CYTK), Curis Inc. (NASDAQ: CRIS), and BioTime Inc. (AMEX: BTX). Free research report on Keryx Biopharma can be accessed at http://www.parklaneadvisor.com/ On Wednesday, December 16, 2015, the NASDAQ Composite ended at 5,071.13, up 1.52%, the Dow Jones Industrial Average advanced 1.28%, to finish the day at 17,749.09, and the S&P 500 closed at 2,073.07, up 1.45%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
CYTK: 8.21 (-0.09), CRIS: 1.69 (-0.10), BTX: 2.74 (-0.03), KERX: 5.93 (-0.12)
